Jeff Bezos Pouring Money Into AI Startup Push, Aggressively
Bezos Expeditions is doubling down on artificial intelligence, backing multiple startups and a high-profile project v...
What Are Target Date Funds Retirement
What Are Target Date Funds Retirement introduces target date funds, explaining how age-based allocations can simplify retirement investing.
19,788 articles
Micron Insiders Dumping at Highest Pace Yet as Stock Surges
Micron insiders are unloading stock at a pace not seen since 2010, even as MU rockets on AI memory demand. This piece...
Reggora Receives Verification Appraisal for UAD 3.6 Forms
Reggora has earned verification from Fannie Mae and Freddie Mac for its UAD 3.6 forms, signaling a shift toward a sin...
Cramer: Cheap Still Cheaper — Salesforce Skeptics Persist
Jim Cramer remains wary of Salesforce as growth slows and CIOs shift budgets to less expensive software. He argues th...
Missed Nvidia Run? SMH Holders Outsized 12-Month Returns
A broad semiconductor ETF beat Nvidia over the past year, reshaping how investors view AI-driven winners and the valu...
IonQ Tumbles as D-Wave, Rigetti Slide in Risk-Off Selloff
Quantum computing stocks moved lower in Monday trading as investors rotated into safer assets amid a broader tech mar...
Missed CRWD’s Rally? This ETF Paid 29% in Six Months
Investors who missed CrowdStrike’s rally found a diversified path higher, as a cybersecurity ETF posted 29% gains ove...
Alec and Hilaria Baldwin Pull Hamptons Estate Again
Alec and Hilaria Baldwin have pulled their $19 million Hamptons estate from the market again, weeks after a price cut...
Steak ‘n Shake Credits Bitcoin Growth, but Usage Isn’t Clear
Steak ’n Shake reports a 16% July lift in U.S. same-store sales and attributes it to Bitcoin adoption, but the absenc...
What Does C3.ai CEO's Sale Mean for Investors
A high-profile insider move can ripple through a stock's story. This article breaks down the C3.ai CEO's $4.2 million...
What This MannKind Director Signals Risk to Royalties
A single director's sale at MannKind raises questions about the durability of royalty streams. This analysis breaks d...
Should Shares CRISPR Therapeutics Be a February Pick?
Biotech investors chase game-changing tech, but CRISPR Therapeutics carries real regulatory milestones and execution ...
Popular Topics
Fable
Smart Money Moves For Everyday Life
Investment Strategies In Energy Sector
Best Index Funds For Retirement
Investment Strategies
Untitled D6eff7ea
Crypto For Beginners
Best Dividend Etfs
Index
Innovative Skincare Clinical
Dutch Salary
Blue Owl
Budget
Ai Healthcare News
Penalty Vs No Penalty Depending On Lock Status